Want to see JP:4880 full AI Analyst Report?
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥294.00 - ¥689.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)77.65K
Market Cap
¥6.57B
Enterprise Value¥2.54K
Total Cash (Recent Filing)¥4.79B
Total Debt (Recent Filing)¥25.26M
Price to Earnings (P/E)96.3
Beta0.91
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.46%
Share Statistics
EPS (TTM)3.56
Shares Outstanding19,847,778
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.79
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5
Revenue Forecast (FY)¥3.70B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal debt and a conservative balance sheet provide durable financial resilience for a biotech firm. This lowers insolvency risk, preserves optionality to fund R&D or partnerships, and allows the company to operate through industry cycles without near-term refinancing pressure.
Positive Cash GenerationConsistent operating and free cash flow across years supports ongoing operations and strategic investments. Positive cash generation reduces dependence on external financing, underpins sustainable funding of clinical programs or commercialization, and improves long-term viability.
Healthy Gross MarginsSustained healthy gross margins indicate the company retains pricing power or cost advantages on core products/services. Even with some compression, strong gross economics provide a structural cushion for profitability recovery if operating expenses and leverage are improved.
Bears Say
Deteriorating Profitability And ReturnsA sharp collapse in returns and margins signals structural operating weakness: reduced earnings power limits internal capital generation, undermines reinvestment capacity and investor returns, and suggests the company must fix core profitability drivers to restore durable growth.
Weakened Cash Quality In 2025When operating cash flow falls below reported earnings it indicates weaker cash conversion and potential accruals or timing issues. This erodes the reliability of internally generated funds, raising funding risk for R&D and making the business more sensitive to external financing conditions.
Inconsistent Revenue Growth And Volatile FCFVolatile revenue and free cash flow reduce predictability of earnings and investment planning. Inconsistent top-line trends complicate scaling and resource allocation for long-term programs, increasing execution risk and lowering confidence in sustained margin recovery.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥294.00 and its highest was ¥689.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥6.57B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Sep 08, 2026 which is in 24 days.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Jun 10, 2026. The company reported ¥1.89 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.46%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,847,778 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of ¥1.89 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.631%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―